Vigeo Therapeutics, Inc. — Form D
Vigeo Therapeutics, Inc. of Cambridge, MA, a company, filed a Form D exempt-offering notice with the SEC on 2021-03-25. The offering totals $17.5M, of which $7.5M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-03-25
- Form: D
- Accession: 0001644338-21-000003
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $17.5M
- Amount sold: $7.5M
- Remaining: $10.0M
- Minimum investment: $7.5M
- Investors: 1
- Date of first sale: 2021-03-15
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-393558
Issuer
- Name: Vigeo Therapeutics, Inc.
- CIK: 0001644338
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2011
- Address: 86 Sherman Street, Cambridge, MA, 02140
- Phone: 617-571-6800
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| James E Mahoney | Director | Cambridge, MA |
| Westerly E Nolin, Ph.D. | Director | Cambridge, MA |
| Stephanie E O'Brien | Director | Cambridge, MA |
| Jing Watnick | Director | Cambridge, MA |
| Jing Watnick | Executive Officer | Cambridge, MA |
| Jason Dinges | Director | New Canaan, CT |
| Stephanie O'Brien | Director | Newton, MA |
| Peter B Finn | Director | Boston, MA |
| Peter B Finn | Executive Officer | Boston, MA |
Other filings by this issuer (2)
More